Cocrystal Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cocrystal Pharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2016 to Q2 2024.
  • Cocrystal Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $148K, a 17.3% decline year-over-year.
  • Cocrystal Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $636K, a 3.25% increase year-over-year.
  • Cocrystal Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $801K, a 6.32% decline from 2022.
  • Cocrystal Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $855K, a 18.1% increase from 2021.
  • Cocrystal Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $724K, a 9.37% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $636K $148K -$31K -17.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $667K $157K -$134K -46% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $801K $158K +$655K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $146K $173K -$470K -73.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $616K $179K -$291K -61.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $907K $291K +$52K +21.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $855K -$497K -$719K -324% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $1.57M $643K +$438K +214% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $1.14M $470K +$392K +503% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $744K $239K +$20K +9.13% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $724K $222K +$288K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $436K $205K -$297K -59.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $733K $78K -$41K -34.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $774K $219K +$112K +105% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $662K -$66K -$163K -168% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-23
Q3 2020 $825K $502K +$394K +365% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $431K $119K +$6K +5.31% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $425K $107K +$74K +224% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $351K $97K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-17
Q3 2019 $108K -$12K -10% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $113K +$6K +5.61% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $33K -$72K -68.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q3 2018 $120K -$22K -15.5% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-09
Q2 2018 $107K +$53K +98.1% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $105K -$107K -50.5% Jan 1, 2018 Mar 31, 2018 10-Q 2018-05-10
Q3 2017 $142K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $54K -$665K -92.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $212K -$507K -70.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q2 2016 $719K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $719K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.